头孢曲松头孢噻肟和头孢呋辛治疗下呼吸道感染的多中心 …

目的 比较头孢曲松、头孢噻肟、头孢呋辛治疗下呼吸道轻中度感染的疗效和安全性。方法 在５家大型教学进行多中心、前瞻性、随机比较。头孢曲松组４８例１ｇ／ｄ，包噻肟组４６例３ｇ／ｄ和头孢呋辛组（４８例２．２５ｇ／ｄ，疗程为７天。均静脉注射，３组１４２例患者，年龄１８－７０岁。一般资料相似。结果３组临床疗效差异无显著性，分别为８１％、８３％、７９％、细菌阳性率为４５％，细菌清除率分别为８０％￣７８％、７５

Multicentre, randomized, prospective and comparative study of ceftriaxone, cefotaxime and cefuroxime in treating mild to moderate respiratory tract infection

OBJECTIVE: The objective of this multicentre, randomized, prospective and comparative study was to evaluate and compare the efficacy and safety of 1 g intravenous ceftriaxone (active ingredient of Rocephin), 3 g intravenous cefoiaxime (active ingredient of clafron), and 2.25 g intavenous cefuroxime (active ingredient of Zinacef). METHOD: In this multicentre, randomized, prospective and comparative study, patients received 1 g of ceftriaxone intravenously once a day (group A), or 1 g of cefotaxime intravenously three times a day (group B), or 0.75 g of cefuroxime intravenously three time a day (group C). 197 patients were enrolled in the study, and in 142 (48 in group A, 46 in group B and 48 in group C) we were able to make an evaluation. RESULT: The overall efficacy (bacteriological eradication plus clinical cure or clear improvement) of ceftriaxone, cefotaxime and cefuroxime were 81%, 83%, 79% respectively (P > 0.05). The eradication rate for three groups were 80%, 78%, 75% (P > 0.05). No adverse events occured. CONCLUSION: Data obtained in our study indicate that for the majority of patients with lower respiratory tract infections, 1 g ceftriaxone, 3 g cefotaxime and 2.25 g cefuroxime are effective and safe, and 7 days therapy is enough, but the use of 1 g ceftriaxone is more convenient.